Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
0.5513
+0.0171 (3.20%)
At close: Jun 2, 2026, 4:00 PM EDT
0.5330
-0.0183 (-3.32%)
Pre-market: Jun 3, 2026, 8:12 AM EDT

Jasper Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
21.5420.7820.4217.0816.5711.41
Research & Development
53.1663.155.8251.7934.6325.42
Total Operating Expenses
74.6983.8876.2468.8651.236.83
Operating Income
-73.03-83.88-76.24-68.86-51.2-36.83
Interest Income
1.281.745.065.20.7-
Other Non-Operating Income (Expense)
16.016.34-0.09---
Total Non-Operating Income (Expense)
16.528.084.975.20.7-
Pretax Income
-56.52-75.8-71.27-63.66-50.5-36.83
Net Income
-56.52-75.8-71.27-63.66-50.5-36.83
Net Income to Common
-56.52-75.8-71.27-63.66-50.5-36.83
Shares Outstanding (Basic)
2219151041
Shares Outstanding (Diluted)
2219151041
Shares Change (YoY)
48.80%31.42%39.72%186.15%220.19%85.99%
EPS (Basic)
-3.23-3.95-4.89-6.18-10.33-26.90
EPS (Diluted)
-3.23-3.95-4.89-6.18-10.33-26.90
Shares Outstanding
28281511.163.83.79
Free Cash Flow
-68.87-77.17-63.15-52.33-46.43-36.11
Free Cash Flow Per Share
-3.08-4.03-4.33-5.01-12.73-31.69
EBITDA
-72.24-82.83-74.87-67.75-50.22-36.46
EBIT
-73.03-83.88-76.24-68.86-51.2-36.83
SEC Filings: 10-K · 10-Q